



期刊导读

7卷12期 2013年6月 [最新]

期刊存档

期刊存档

期刊订阅

在线订阅

邮件订阅

RSS

资质及晋升信息

作者查稿

写作技巧

投稿方式

作者指南

编委会

建议我们

会员服务

广告合作

继续教育

您的位置: [首页](#)>> 文章摘要[中文](#)[English](#)

地氯雷他定治疗变应性鼻炎的随机对照试验的Meta分析

张雷波, 陈始明, 孔勇刚, 丁永军, 陶泽璋

4300060 武汉, 武汉大学人民医院耳鼻咽喉头颈外科

陈始明, Email: shimingchen@163.com

湖北省自然科学基金(2012FFB04312)

摘要:目的 评价地氯雷他定治疗变应性鼻炎的疗效及其安全性。方法 计算机检索SCI、Pubmed、图书馆、万方、中国知网中关于地氯雷他定治疗变应性鼻炎的随机对照试验,同时追索纳入文献均从建库检索到2012年12月。由两名评价员独立筛查文献,采用Jadad修订版的量表对纳入的文献选取资料,对符合质量标准的随机对照试验(RCT)进行Meta分析,比较地氯雷他定组和安慰剂组总的症状评分、总的非鼻部症状评分、单一鼻部症状评分、生活质量评价和安全性评估。统计学分析结果 共纳入9个RCT。地氯雷他定(5 mg/d)可有效改善变应性鼻炎患者的症状,可降低患者总的症状评分、总的非鼻部症状评分及部分单一的鼻部症状评分。地氯雷他定可有效提高生活质量,降低分(P均<0.05)。地氯雷他定的不良反应发生率与安慰剂组相似,不良反应发生差异无统计学意义。地氯雷他定(5 mg/d)可以有效缓解患者的症状,改善患者的生活质量,且不良反应发生率与对照组相

关键词:鼻炎; 随机对照试验; Meta分析; 地氯雷他定

[评论](#) [收藏](#) [全](#)

文献标引: 张雷波, 陈始明, 孔勇刚, 丁永军, 陶泽璋. 地氯雷他定治疗变应性鼻炎的随机对照试验的Meta分析

杂志: 电子版, 2013, 7(12):5425-5431.

参考文献:

- [1] Bousquet J, Van CP, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. *Immunol*, 2001, 108:S147-S334. :[PubMed]
- [2] Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. *Lancet*, 2011, 378:21
- [3] Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. *Allergy*, 2007, 62:17-25. :[PubMed]
- [4] Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a nonsedating histamine H1 receptor antagonist. 1st communication:receptor selectivity, activity, and antiallergenic effects. *Arzneimittelforschung*, 2000, 50:345-352. :[PubMed]
- [5] Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. *J Allergy Clin Immunol*, 2003, 111:617-622. :[PubMed]

- [6] Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a study. *Int Immunopharmacol*, 2005, 5:1800–1808. :[\[PubMed\]](#)
- [7] Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action, and safety of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects from the Environmental Exposure Unit (EEU). *Int J Clin Pract*, 2004, 58:109–118. :[\[PubMed\]](#)
- [8] Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in persistent seasonal allergic rhinitis [ISRCTN32042139]. *BMC Fam Pract*, 2002, 3:14. :[\[PubMed\]](#)
- [9] Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bi-daily desloratadine 5 mg in seasonal allergic rhinitis patients. *Allergy*, 2009, 64:158–165. :[\[PubMed\]](#)
- [10] Reinartz SM, Overbeek SE, Kleinjan A, et al. Fokkens Desloratadine reduces systemic inflammation following nasal provocation in allergic rhinitis and asthma patients. *Allergy*, 2009, 64:1307. :[\[PubMed\]](#)
- [11] Pradalier A, Neukirch C, Dreyfus I, et al. Desloratadine improves quality of life and severity in patients with allergic rhinitis. *Allergy*, 2007, 62:1331–1334. :[\[PubMed\]](#)
- [12] Holmberg K, Tonnel AB, Dreyfus I, et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. *Allergy*, 2009, 64:1663–1670. :[\[PubMed\]](#)
- [13] Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. *Allergy*, 2009, 64:1516–1523. :[\[PubMed\]](#)
- [14] Canonica GW, Tarantini F, Compalati E, et al. Efficacy of desloratadine in the treatment of allergic rhinitis: a metaanalysis of randomized, double-blind, controlled trials. *Allergol Immunobiol*, 2009, 57:10–16. :[\[PubMed\]](#)
- [15] Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. *Allergy*, 2001, 56:14–20. :[\[PubMed\]](#)
- [16] Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in patients with seasonal allergic rhinitis and nasal congestion. *Ann Allergy Asthma Immunol*, 2002, 88:33–38. :[\[PubMed\]](#)
- [17] Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for assessment of the efficacy, safety and pharmacology of desloratadine. *Allergy*, 2004, 59:10–16. :[\[PubMed\]](#)
- [18] DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical experience. *Clin Dermatol*, 2007, 25:271–283. :[\[PubMed\]](#)
- [19] Gupta S, Khalilieh S, Kantesaria B, et al. Pharmacokinetics of desloratadine in children aged 2 to 11 years. *Br J Clin Pharmacol*, 2007, 63:534–540. :[\[PubMed\]](#)
- [20] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. *Int J Pediatr Otorhinolaryngol*, 2007, 71:103–107. :[\[PubMed\]](#)

张雷波，陈始明，孔勇刚，丁永军，陶泽璋. 中华临床医师杂志：电子版
2013;7(12):5425-5431.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

费贤树，曾谊，林云霞，宋梅梅. 中华临床医师杂志：电子版
2013;7(12):5432-5438.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)